Related Experiment Video
Updated: Jul 10, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Pegaptanib sodium for ocular vascular disease.
Dhananjay Shukla1, Perumalsamy Namperumalsamy, Mauro Goldbaum
1Retina-Vitreous Service, Aravind Eye Hospital and Postgraduate Institute, Anna Nagar, Madurai, India.
Indian Journal of Ophthalmology
|October 24, 2007
Summary
Pegaptanib sodium (Macugen) is a novel RNA aptamer that effectively treats age-related macular degeneration by inhibiting vascular endothelial growth factor (VEGF). It demonstrates a strong safety profile and potential for other ocular vascular diseases.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Pathologic ocular neovascularization and vascular permeability are driven by specific vascular endothelial growth factor (VEGF) isoforms.
- Pegaptanib sodium is a selective RNA aptamer designed to target these disease-causing VEGF isoforms.
Purpose of the Study:
- To evaluate the efficacy and safety of pegaptanib sodium in treating ocular vascular diseases.
- To highlight pegaptanib's role as a first-in-class therapeutic aptamer and VEGF inhibitor.
Main Methods:
- Clinical trials were conducted after extensive preclinical development.
- Pegaptanib sodium was administered to patients with various ocular vascular conditions.
Main Results:
- Pegaptanib demonstrated efficacy in treating choroidal neovascularization associated with age-related macular degeneration.
- A favorable ocular and systemic safety profile was observed over three years of therapy.
- Potential therapeutic benefits were suggested for diabetic macular edema, proliferative diabetic retinopathy, and retinal vein occlusion.
Conclusions:
- Pegaptanib sodium is an effective treatment for specific ocular vascular diseases, notably age-related macular degeneration.
- Its safety profile supports long-term therapeutic use.
- Pegaptanib represents a significant advancement as the first approved therapeutic aptamer and VEGF inhibitor for ocular conditions.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...